POET and Mitsubishi Electric Collaborate to Develop 3.2T Optical Engines for AI Networks
September 19, 2024 07:35 ET
|
POET Technologies Inc.
TORONTO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
September 19, 2024 07:30 ET
|
Psyence Biomedical Ltd.
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into a conditional share sale agreement...
Shock Top Announces its Official Craft Beer Sponsorship of University of Missouri Athletics
September 19, 2024 07:12 ET
|
Tilray Brands, Inc.
Shock Top is proud to contribute to the collegiate experience by promoting a culture of inclusivity, support, and pride that transcends the game.
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
September 19, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for...
Arqit Quantum Inc. Announces 25:1 Reverse Share Split
September 19, 2024 07:00 ET
|
Arqit
LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ) (“Arqit” or the “Company”), a leader in quantum safe encryption, today announces that, following approval by the...
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
September 19, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Achilles Therapeutics Announces Strategic Update
September 19, 2024 07:00 ET
|
Achilles Therapeutics PLC
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON,...
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
September 19, 2024 07:00 ET
|
ACELYRIN, INC.
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
September 19, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE)...
FactSet Reports Results for Fourth Quarter 2024
September 19, 2024 07:00 ET
|
FactSet Research Systems Inc.
Q4 GAAP revenues of $562.2 million, up 4.9% from Q4 2023.Organic Q4 ASV plus professional services of $2,272.8 million, up 4.8% year over year.Q4 GAAP operating margin of 22.7%, up approximately 110...